Last reviewed · How we verify

Dapagliflozin (Forxiga) — Competitive Intelligence Brief

Dapagliflozin (Forxiga) (Dapagliflozin (Forxiga)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes, Cardiovascular.

marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin (Forxiga) (Dapagliflozin (Forxiga)) — National Institute of Cardiology, Warsaw, Poland. Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dapagliflozin (Forxiga) TARGET Dapagliflozin (Forxiga) National Institute of Cardiology, Warsaw, Poland marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)
SGLT2 inhibitor, GLP-1 RA SGLT2 inhibitor, GLP-1 RA Brigham and Women's Hospital marketed SGLT2 inhibitor / GLP-1 receptor agonist combination SGLT2 and GLP-1R
SGLT2 Inhibition SGLT2 Inhibition Zhongshan Hospital Xiamen University marketed SGLT2 inhibitor SGLT2 (Sodium-Glucose Cotransporter 2)
Empagliflozin (Jardiance®) Empagliflozin (Jardiance®) University Hospital Tuebingen marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)
Semaglutide, Empagliflozin Semaglutide, Empagliflozin University Medical Center, Kazakhstan marketed GLP-1 receptor agonist + SGLT2 inhibitor combination GLP-1 receptor; SGLT2
Keverprazan 10 days Keverprazan 10 days Second Affiliated Hospital, School of Medicine, Zhejiang University marketed SGLT2 inhibitor SGLT2
SGLT2 Inhibitors SGLT2 Inhibitors Pharmaceuticals and Medical Devices Agency, Japan marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

  1. Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
  2. Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
  3. Takeda · 10 drugs in this class
  4. Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
  5. Hanmi Pharmaceutical Company Limited · 9 drugs in this class
  6. Addpharma Inc. · 9 drugs in this class
  7. GlaxoSmithKline · 7 drugs in this class
  8. AO GENERIUM · 7 drugs in this class
  9. Merck Sharp & Dohme LLC · 7 drugs in this class
  10. Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin (Forxiga) — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-forxiga. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: